Monoacylglycerol Lipase (MAGL) is a serine hydrolase that is essential in catalyzing the hydrolysis of monoglycerides into glycerol and fatty acids. By converting the plentiful endocannabinoid 2-arachidaoylglycerol into arachidonic acid, the precursor of prostaglandins and other inflammatory mediators, MAGL connects the endocannabinoid and eicosanoid systems.
MAGL is a key enzyme that regulates the levels of 2-AG, an important lipid with a variety of neuroprotective effects; ii) when MAGL is inactive, 2-AG levels in the brain are elevated and AA levels are decreased, which reduces the production of pro-inflammatory prostaglandins, which reduces neuroinflammation; and iii) MAGL controls the levels of free fatty acids (FFAs) in aggressive cancer cells, and this MAGL-promote MAGL is becoming a potentially effective drug target for a number of diseases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73518 | N-Arachidonyl maleimide | 876305-42-9 | N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 140 nM. |
|
V45847 | WWL-123 | 1338575-41-9 | WWL-123 is a novel, potent andselective ABHD6 inhibitor with antiepileptic effects. |
|
V17481 | WWL70 | 947669-91-2 | WWL-70 is a novel, potent inhibitor of α/β-hydrolase domain 6 (ABHD6) with IC50 of 70 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
